Large language models (LLMs) may serve as a valuable supplement to oncology documentation workflows by detecting and ...
FDA NDA acceptance positions zipalertinib for post-systemic-therapy EGFR ex20ins NSCLC, with a February 27, 2027 PDUFA target ...
Heather Stefanski, MD, PhD, representing the National Marrow Donor Program, provides a detailed overview of the ACCESS study ...
Explore why rare HER2-mutant NSCLC is highly aggressive and how broad NGS testing helps identify candidates for new ...
Explore why rare HER2-mutant NSCLC is highly aggressive and how broad NGS testing helps identify candidates for new ...
In this segment on advanced renal cell carcinoma, Dr. Wulff explores how the potential incorporation of belzutifan-based ...
FDA accepted an RTOR sBLA and granted priority review for zanidatamab-hrii combinations as first-line therapy in HER2+ ...
Rusfertide may reduce phlebotomy needs in polycythemia vera, offering a convenient weekly self-injection option that could ...
The investigational agent IMNN-001 is demonstrating promising potential to extend survival in patients with advanced ovarian ...
Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse ...
A new Bayesian statistical framework uses the residual cancer burden score to better predict long-term survival in breast ...
Rashmi Chugh, MD, of the University of Michigan, outlines a strategic roadmap for the future development of ozekibart in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results